



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Maria-Luisa Maccicchini and Xue-Feng Pei

Serial No.: 10/021,177

Art Unit: 1614

Filed October 30, 2001

Examiner: William R. Jarvis

For: *METHOD FOR MODULATION, STIMULATION, AND INHIBITION OF GLUTAMATE REUPTAKE*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including six (6) pages of Form PTO-1449 and copies of fifty-five (55) documents cited therein, and a copy of the International Search Report mailed October 23, 2002 in PCT/US01/48448, which corresponds to the above-identified application.

Enclosed is a check for \$240.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission.

However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

05/28/2003 MMDHAMM1 00000040 10021177

01 FC:1806

180.00 OP

Refund Ref:
05/28/2003 MMDHAMM1 0000127560

CHECK Refund Total: \$60.00

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,428,069	06-27-1995	Skolnick et al.	514/531
5,658,782	08-19-1997	Amara et al.	435/365
5,731,348	03-24-1998	Gu	514/561
5,739,284	04-14-1998	Hediger et al.	530/350
5,776,774	07-07-1998	Amara et al.	435/325
5,840,516	11-24-1998	Amara et al.	435/29
5,882,926	03-16-1999	Amara et al.	435/325
5,912,171	06-15-1999	Amara et al.	435/325
5,919,628	07-06-1999	Amara et al.	435/6
5,919,699	07-06-1999	Amara et al.	435/325
5,932,424	08-03-1999	Amara et al.	435/6
5,989,825	11-23-1999	Amara et al.	435/6
6,020,479	02-01-2000	Amara et al.	536/23.5
6,060,307	05-09-2000	Amara et al.	435/317.1
6,074,828	06-13-2000	Amara et al.	435/6
6,090,560	07-18-2000	Amara et al.	435/6
6,100,085	08-08-2000	Amara et al.	435/317.1

Foreign Documents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Country</u>
0 342 558	11-23-1989	Searle & Co.	EP
0 913 389	05-06-1999	Nippon Chemiphar Co.	EP
WO 96/25387	08-22-1996	Symphony Pharm. Inc.	PCT
WO 98/38208	09-03-1998	Bearsden Bio Inc.	PCT
WO 99/38839	08-05-1999	Kumugai Toshihito	PCT
WO 00/27374	05-18-2000	Stys	PCT

Publications

ARRIZA, et al., "Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance" *Proc. Natl. Acad. Sci. U.S.A.* 94(8): 4155-4160 (1997).

ARRIZA, et al., "Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex", *J. Neurosci.* 14(9): 5559-5569 (1994).

BAKER, et al., "4-alkylidenyl glutamic acids, potent and selective GluR5 agonists," *Bioorg. Med. Chem. Lett.* 10(16): 1807-1810 (2000).

BRIDGES, et al., "A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system" *Curr. Pharmaceut. Des.* 5(5): 363-379 (1999).

BRAÜNER-OSBORNE, et al., "Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors," *Eur. J. Pharm.* 335(2-3): R1-R3 (1997).

CARROLL, et al., "Regional distribution of low affinity kainate receptors in brain of *Macaca fascicularis* determined by autoradiography using [3H](2S,4R)-4-methylglutamate" *Neurosci. Lett.* 255(2): 71-74 (1998).

FAIRMAN, et al., "An excitatory amino-acid transporter with properties of a ligand-gated chloride channel," *Nature* 375(6532): 599-603 (1995).

FURUTA et al., "Glutamate transporter protein subtypes are expressed differentially during rat CNS development," *J. Neurosci.* 17(21): 8363-8375 (1997).

GEGELASHVILI, et al., "High affinity glutamate transporters: regulation of expression and activity" *Mol Pharmacol* 52(1):6-15 (1997).

GU, et al., "Diastereoselective synthesis of (2S,4S)-4-methylglutamic acid (SYM 2081): a high affinity and selective ligand at the kainate subtype of glutamate receptors," *Bioorg. Med. Chem. Lett.* 5(17): 1973-1976 (1995).

GU, et al., "Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors," *J Med Chem* 38(14):2518-20 (1995).

KANAI, et al., "Primary structure and functional characterization of a high-affinity glutamate transporter" *Nature* 360(6403): 467-471 (1992).

KRASNOV, et al., "Stereo-directed synthesis of 4 hydroxy-glutamic acid enantiomers and the study of their inhibiting properties with respect to glutamine synthetase," *Khimiko-Farmatsevticheskii Zhurnal* 18(6): 655-659 (1984), abstract only.

KROGSGAARD-LARSEN, et al., "Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure," *Eur. J. Med. Chem.* 31(7): 515-537 (1996).

LI, et al., "The Na⁺-dependent binding of [3H]L-aspartate in thaw-mounted sections of rat forebrain" *Exp. Brain Res.* 97(3): 415-422 (1994).

LIPTON, et al., "Excitatory amino acids as a final common pathway for neurologic disorders," *N Engl J Med* 330(9):613-22 (1994).

MCLENNAN, "Actions of excitatory amino acids and their antagonism," *Neuropharmacol.* 13(6): 449-454 (1974).

PEDREGAL, et al., "4-alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists," *J. Med. Chem.* 43(10): 1958-1968 (2000).

PELLETIER & HESSON, "A mild preparation of amino acid N-acylsulfonamides," *Synlett* 11: 1141-1142 (1995).

PINES, et al., "Cloning and expression of a rat brain L-glutamate transporter" *Nature* 360(6403): 464-467 (1992).

ROBINSON, et al., "Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system" *Adv. Pharmacol* 37: 69-115 (1997).

ROTHSTEIN, et al., "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate" *Neuron* 16(3):675-686 (1996).

SHIMAMOTO, et al., "DL-threo-beta-benzyloxypartate, a potent blocker of excitatory amino acid transporters" *Mol. Pharmacol.* 53(2): 195-201 (1998).

STARR, "Glutamate/Dopamine D₁/D₂ balance in the basal ganglia and its relevance to Parkinson's disease," *Synapse* 19(4): 264-293 (1995).

STORCK, et al., "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain." *Proc. Natl. Sci. U.S.A.* 89(22): 10955-10959 (1992).

TA, et al., "SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain," *Brain Res.* 858(1): 106-120 (2000).

TOMS, et al., "A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes" *Neuropharmacology* 36(11-12): 1483-1488 (1997).

TRIST, "Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications," *Pharm. Acta Helvet.* 74(2-3): 221-229 (2000).

VANDENBERG, et al., "Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2" *Mol. Pharmacol.* 51(5): 809-815 (1997).

VANDENBERG, "Molecular pharmacology and physiology of glutamate transporters in the central nervous system," *Clin. Exp. Pharmacol. Physiol.* 25(6): 393-400 (1998).

WINTER & UEDA, "Glutamate uptake system in the presynaptic vesicle: glutamic acid analogs as inhibitors and alternate substrates," *Neurochem. Res.* 18(1): 79-85 (1993).

ZHOU, et al., "(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors" *J. Pharmacology Exper. Therapeutics* 280(1):422-427 (1997).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,




Patrea L. Pabst
Reg. No. 31,284

Dated: May 23, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

Pam
X 8569


U.S.S.N.: 10/021,177
Filed: October 30, 2001
INFORMATION DISCLOSURE STATEMENT



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313.

Date: May 22, 2003


Aisha Wyatt

ATL1 #533506 v1